Search results
Results from the WOW.Com Content Network
The European Journal of Cancer (EJC) integrates preclinical, digital, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care.
Aims & Scope. The European Journal of Cancer (EJC) integrates preclinical, digital, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care.
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
Inadequate Staging and Excessive Surveillance Imaging: Evaluating the Magnitude of Benefit of Targeted Therapies in Lung Cancer
Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC.
Results. Between 17th June 2019 and 23rd August 2021, 45 patients were enrolled and received at least one dose of KN026, including 27 patients in the high-level HER2 cohort, 14 patients in the low-level HER2 cohort and four patients who had no HER2 expression.
These data can help support a more policy-focused cancer research agenda for individual European governments and charitable and philanthropic organisations and stimulate joining efforts across Europe to create a more systematic and structured approach to cancer prevention.
Blinatumomab is a bispecific T cell engager used in lymphoblastic B cell leukemia. •. Systemic sclerosis is an autoimmune disease with causative B cell abnormalities. •. We here report the first successful use of blinatumomab in systemic sclerosis.